Crossmark

Pulmonary PET imaging confirms preferential lung target occupancy of an inhaled bronchodilator

Crossref DOI link: https://doi.org/10.1186/s13550-019-0479-8

Published Online: 2019-01-29

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schou, Magnus https://orcid.org/0000-0002-4314-2418
Ewing, Pär

Cselenyi, Zsolt

Fridén, Markus

Takano, Akihiro

Halldin, Christer

Farde, Lars
Funding

Funding for this research was provided by:

AstraZeneca
License Information

Text and Data Mining valid from 2019-01-29
More Information

Article History

Received: 7 November 2018

Accepted: 21 January 2019

First Online: 29 January 2019

Ethics approval and consent to participate

: The study was approved by the Animal Ethics Committee of the Swedish Animal Welfare Agency (Dnr 452/11) and was performed according to the “Guidelines for planning, conducting and documenting experimental research” (Dnr 4820/06-600) of Karolinska Institutet, the “Guide for the Care and Use of Laboratory Animals” [], the AstraZeneca Bioethical Policy and the EU Directive 2010/63/EU on the protection of animals used for scientific purposes.

: Not applicable

: MF, LF. MS, PE, ZC, MF and LF are employees at AstraZeneca. No other potential competing interest relevant to this article exist.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.